Research News

Customer questions_635
Customer questions_636

  

Improving Quality of Life of IBD patients with probiotics

 

In the past decade, inflammatory bowel disease (IBD) has emerged as a public health challenge worldwide. IBD is associated with significant psychosocial burden and reduced quality of life. Since a clear association has been found between IBD and gut microbiota disturbances, probiotic interventions could be a promising approach in the management of IBD.

Read more

 

 


Inflammatory bowel disease of which ulcerative colitis (UC), pouchitis, and Crohn’s disease (CD) are subtypes, is a chronic inflammation of (parts of) the intestinal tract. IBD affects over 1.5 million people in North America and 2 million people in Europe, with increasing prevalence. [1] IBD symptoms include amongst others diarrhoea, abdominal pain, weight loss, or anaemia. The course of IBD can be chronic and unpredictable, with embarrassing and painful symptoms, leaving patients worried about many aspect of life such as bowel control, fatigue, social isolation, and fear of developing cancer or needing surgery. 

Subtypes of IBD, based on which part of the GI-tract is affected.

COPY The three levels of probiotic action_1573

IBD puts a great burden on a patient’s day-to-day functioning and severely affects quality of life. [2] Over the past decades, studies using QoL end- point in IBD have increased dramatically and reviews have found that individuals with IBD reported poorer QoL than healthy individuals or those with other health conditions. [2,3]

 

 

The pathogenesis of IBD is not completely understood but a current hypothesis is that the homeostasis between microbiota, intestinal barrier and immune cells is disrupted, resulting in a chronic state of inflammation. [4] Current treatments of IBD usually includes medication such as corticosteroids, antibiotics or immunomodulators. Often surgery is needed at some point in the disease course, particularly for those with CD. Alternative therapies aimed at restoring microbial disturbances would be a safer and more sustainable approach.

 

 

Read more about Winclove's probiotic formulation Ecologic® 825 focused on improving QoL of IBD patients 

 

In a healthy situation, commensal bacteria maintain a symbiotic relationship with the host and modulate a proper functioning of the immune system. Maintaining  intestinal microbial homeostasis has been shown to prevent occurrence of IBD. In case of disturbances, microbial management therapies such as probiotics are an effective way to modulate the gut microbiota. The potential beneficial effects of probiotics have been thought to include inhibition of invasion of pathogenic bacteria, improvement the epithelial barrier function and immunomodulation. [5]

 

Many studies have been performed on the role probiotics can play in managing IBD, however, not always with consistent findings [6]. The diverse results can be explained by differences in dose, duration, strain-specific effects of probiotics, or personal microbial composition. Despite the contradicting study outcomes, the clear association between gut dysbiosis and IBD and lack of safe and sustainable treatment options, microbial therapies are a promising and becoming a more common approach to manage IBD. Selecting the right combination of probiotic strains that target the microbial disturbances underlying the disease, understanding how a patient’s gut microbiota respond to the intervention, and how QoL is improved in the end, has become very important in this.

 

 

References

1: NG SC, et al. Woldwide incidence and prevalence of inflammatory bowel disaes in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769-2778

2 Knowles SR et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analysis part 1. Inflamm Bowel Dis 2018;24940:742-751.

3 Casellas F et al. health related quality of life in inflammatory bowel disease. Gastroenterol Int. 1996;9:53-61.

4 Ananthakrishnan AN, et al. Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis. Sci. 2015. 60;290-298.

5 Dos Reis SA et al. Review of the mechanisms of probiotic actions in the prevention of colorectal cancer. Nutr. Res. 2017;37:1-19.

6 Eom T et al. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease. J Microbiol. 2018;56930:189-198.

 

 

 

 

 

 

 

Improving QoL of IBD patients with probiotics

5/11
Klik op het menu voor inhoud en andere functies.

Gebruik de pijlen aan de zijkant om door het magazine te bladeren.
Loading ...